

COMPANY REGISTRATION NUMBER 06157784

PROSTATE CANCER TRADING LIMITED
FINANCIAL STATEMENTS
31 MARCH 2022



PROSTATE CANCER TRADING LIMITED

FINANCIAL STATEMENTS

YEAR ENDED 31 MARCH 2022

CONTENTS	PAGE
Administrative details	1
The directors' report	2
Independent auditor's report to the members	4
Profit and loss account	7
Balance sheet	8
Statement of changes in equity	9
Notes to the financial statements	10

PROSTATE CANCER TRADING LIMITED

DIRECTORS AND AUDITOR

The board of directors

Charles Packshaw
Lynne Robb
George Jenkins (resigned 18.02.22)
Nicola Tallett (appointed 10.06.21)

Registered office

Fourth Floor, The Counting House
53 Tooley Street
London SE1 2QN

Auditor

Haysmacintyre LLP
10 Queen Street
London
EC4R 1AG

PROSTATE CANCER TRADING LIMITED

THE DIRECTORS' REPORT

YEAR ENDED 31 MARCH 2022

The directors have pleasure in presenting their report and the financial statements of the company for the year ended 31 March 2022.

PRINCIPAL ACTIVITIES

Prostate Cancer Trading Limited is a wholly-owned subsidiary of the charity Prostate Cancer UK (Registered charity number: 1005541). Its sole purpose is to raise funds through trading activity including marketing, corporate sponsorship and sales of goods.

DIRECTORS

The directors who served the company during the year were as follows:

Charles Packshaw

Lynne Robb

George Jenkins (resigned 18.02.22)

Nicola Tallett (appointed 10.06.21)

DIRECTORS' RESPONSIBILITIES

The directors are responsible for preparing the Directors' Report and the financial statements in accordance with applicable law and regulations.

Company law requires the directors to prepare financial statements for each financial year. Under that law the directors have elected to prepare the financial statements in accordance with United Kingdom Generally Accepted Accounting Practice (United Kingdom Accounting Standards and applicable law). Under company law the directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the company and the profit or loss of the company for that period.

In preparing these financial statements, the directors are required to:

- select suitable accounting policies and then apply them consistently;
- make judgements and accounting estimates that are reasonable and prudent;
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the company will continue in business.

The directors are responsible for keeping adequate accounting records that are sufficient to show and explain the company's transactions and disclose with reasonable accuracy at any time the financial position of the company and to enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

PROSTATE CANCER TRADING LIMITED

THE DIRECTORS' REPORT *(continued)*

YEAR ENDED 31 MARCH 2022

DONATIONS

During the year the company made the following donation under gift aid to the company's parent undertaking, Prostate Cancer UK:

	2022 £	2021 £
Charitable donations	<u>31,738</u>	<u>159,142</u>

AUDITOR

Haysmacintyre LLP is deemed to be re-appointed under section 487(2) of the Companies Act 2006.


SMALL COMPANY PROVISIONS

This report has been prepared in accordance with the special provisions for small companies under Part 15 of the Companies Act 2006.

Registered office:
Fourth Floor, The Counting House
53 Tooley Street
London SE1 2QN

Approved by the directors on 28 July 2022.

Signed on behalf of the directors:



L. Robb
Director

PROSTATE CANCER TRADING LIMITED

INDEPENDENT AUDITOR'S REPORT TO THE MEMBERS OF PROSTATE CANCER TRADING LIMITED

We have audited the financial statements of Prostate Cancer Trading Limited for the year ended 31 March 2022 which comprise Profit and Loss Account, the Balance Sheet, the Statement of Changes in Equity and the related notes. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice), including FRS102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland".

In our opinion the financial statements:

- give a true and fair view of the state of the company's affairs as at 31 March 2022, and of its profit/ loss for the year then ended;
- have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and
- have been prepared in accordance with the requirements of the Companies Act 2006.

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditor's responsibilities for the audit of the financial statements section of our report. We are independent of the company in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC's Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Conclusions relating to going concern

We have nothing to report in respect of the following matters in relation to which the ISAs (UK) require us to report to you where:

- the directors' use of the going concern basis of accounting in the preparation of the financial statements is not appropriate; or
- the directors have not disclosed in the financial statements any identified material uncertainties that may cast significant doubt about the company's ability to continue to adopt the going concern basis of accounting for a period of at least twelve months from the date when the financial statements are authorised for issue.

Other information

The directors are responsible for the other information. The other information comprises the information included in the annual report, other than the financial statements and our auditor's report thereon. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon.

PROSTATE CANCER TRADING LIMITED

INDEPENDENT AUDITOR'S REPORT TO THE MEMBERS OF PROSTATE CANCER TRADING LIMITED

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether there is a material misstatement in the financial statements or a material misstatement of the other information. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.

We have nothing to report in this regard.

Opinions on other matters prescribed by the Companies Act 2006

In our opinion, based on the work undertaken in the course of the audit:

- the information given in the directors' report for the financial year for which the financial statements are prepared is consistent with the financial statements; and
- the directors' report has been prepared in accordance with applicable legal requirements.

Matters on which we are required to report by exception

In the light of our knowledge and understanding of the company and its environment obtained in the course of the audit, we have not identified material misstatements in the directors' report.

We have nothing to report in respect of the following matters in relation to which the Companies Act 2006 requires us to report to you if, in our opinion:

- adequate accounting records have not been kept, or returns adequate for our audit have not been received from branches not visited by us; or
- the financial statements are not in agreement with the accounting records and returns; or
- certain disclosures of directors' remuneration specified by law are not made; or
- we have not received all the information and explanations we require for our audit; or
- the directors were not entitled to prepare the financial statements in accordance with the small companies regime and take advantage of the small companies' exemptions in preparing the directors' report and from the requirement to prepare a strategic report,

PROSTATE CANCER TRADING LIMITED

INDEPENDENT AUDITOR'S REPORT TO THE MEMBERS OF PROSTATE CANCER TRADING LIMITED

Responsibilities of directors

As explained more fully in the directors' responsibilities statement set out on page 2, the directors are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the directors determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the directors are responsible for assessing the company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the directors either intend to liquidate the company or to cease operations, or have no realistic alternative but to do so.

Auditor's responsibilities for the audit of the financial statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

A further description of our responsibilities for the audit of the financial statements is located on the Financial Reporting Council's website at: <https://www.frc.org.uk/Our-Work/Audit/Audit-and-assurance/Standards-and-guidance/Standards-and-guidance-for-auditors/Auditors-responsibilities-for-audit/Description-of-auditors-responsibilities-for-audit.aspx>. This description forms part of our auditor's report

Use of our report

This report is made solely to the company's members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the company's members those matters we are required to state to them in an auditor's report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the company and the company's members as a body, for our audit work, for this report, or for the opinions we have formed.



Richard Weaver FCA
For and on behalf of:
Haysmacintyre LLP
10 Queen Street Place
London
EC4R 1AG

Date: 23 August 2022

PROSTATE CANCER TRADING LIMITED

PROFIT AND LOSS ACCOUNT

YEAR ENDED 31 MARCH 2022

	Note	2022 £	2021 £
TURNOVER		418,852	394,767
Cost of sales		<u>(219,310)</u>	<u>(138,842)</u>
GROSS PROFIT		199,542	255,925
Administrative expenses		<u>(167,840)</u>	<u>(96,953)</u>
OPERATING PROFIT	2.	<u>31,702</u>	<u>158,972</u>
Interest receivable		<u>36</u>	<u>170</u>
PROFIT ON ORDINARY ACTIVITIES BEFORE TAXATION		31,738	159,142
Tax on profit on ordinary activities		-	-
PROFIT FOR THE FINANCIAL YEAR		<u><u>31,738</u></u>	<u><u>159,142</u></u>

PROSTATE CANCER TRADING LIMITED


BALANCE SHEET

31 MARCH 2022

	Note	2022 £	2021 £
FIXED ASSETS			
Website development		-	13,500
CURRENT ASSETS			
Stock	3	92,725	52,651
Prepayments & Accrued income	4	12,110	16,204
Debtors	5	54,837	1,768
Cash at bank		88,783	427,134
		<u>248,455</u>	<u>497,757</u>
CREDITORS: Amounts falling due within one year	6	<u>(248,355)</u>	<u>(511,157)</u>
NET CURRENT ASSETS		<u>100</u>	<u>(13,400)</u>
TOTAL ASSETS LESS CURRENT LIABILITIES		<u>100</u>	<u>100</u>
CAPITAL AND RESERVES			
Called-up equity share capital	7	<u>100</u>	<u>100</u>
SHAREHOLDERS' FUNDS		<u>100</u>	<u>100</u>

These financial statements have been prepared in accordance with the special provisions for small companies under Part 15 of the Companies Act 2006 and with the provisions of FRS 102 Section 1A – small entities.

These financial statements were approved by the directors and authorised for issue on 28 July 2022 and are signed on their behalf by:



L Robb

Director

Company Registration Number: 06157784

The notes on page 10 to 12 form part of these financial statements.

PROSTATE CANCER TRADING LIMITED

STATEMENT OF CHANGES IN EQUITY

31 MARCH 2022

	Called up share capital £	Retained earnings £	Total £
At 1 April 2021	100	-	100
Profit for the year	-	31,738	31,738
Payment to parent charity under Gift Aid	-	(31,738)	(31,738)
At 31 March 2022	100	-	100

	Called up share capital £	Retained earnings £	Total £
At 1 April 2020	100	-	100
Profit for the year	-	159,142	159,142
Payment to parent charity under Gift Aid	-	(159,142)	(159,142)
At 31 March 2021	100	-	100

PROSTATE CANCER TRADING LIMITED

NOTES TO THE FINANCIAL STATEMENTS

31 MARCH 2022

1. ACCOUNTING POLICIES

General information

Prostate Cancer Trading Limited is a private company limited by shares incorporated in England and Wales. The financial statements are presented in sterling which is the functional currency of the company, and rounded to the nearest £1.

Basis of accounting

The financial statements have been prepared under the historical cost convention, and in accordance with the Companies Act 2006 (provisions applicable to small companies) and Section 1A of Financial Reporting Standard 102, the Financial Reporting Standard applicable in the UK.

Turnover

Turnover shown in the profit and loss account represents amounts receivable by the company during the period, exclusive of Value Added Tax.

Stock

Stock consists of purchased goods for resale, which are valued at the lower of cost and net realisable value on a first-in, first-out basis.

Provision is made for any obsolete or slow-moving items.

Debtors

Short term debtors are measured at transaction price, less any impairment.

Fixed Assets

Expenditure on individual tangible assets with a value greater than £5,000 is capitalised. Tangible assets are stated at depreciated historical cost. Depreciation is provided on a straight line basis at the following annual rates in order to write off each asset over its estimated useful life:

Website development	33%
---------------------	-----

Cash and cash equivalents

Cash is represented by cash in hand and deposits with financial institutions repayable without penalty on notice of not more than 24 hours. Cash equivalents are highly liquid investments that mature in no more than three months from the date of acquisition and that are readily convertible to known amounts of cash with insignificant risk of change in value.

Creditors

Short term creditors are measured at the transaction price.

PROSTATE CANCER TRADING LIMITED

NOTES TO THE FINANCIAL STATEMENTS

31 MARCH 2022

Judgements in applying accounting policies and key sources of estimation uncertainty

The company may be required to make estimates and assumptions concerning the future. These estimates and judgements are based on historical experience and other factors, including expectations of future events that are believed to be reasonable under the circumstances. The resulting accounting estimates will, by definition, seldom equal the related actual results.

There were no principal areas where judgement was exercised during the year.

2. OPERATING PROFIT

Operating profit is stated after charging:

	2022 £	2021 £
Directors' remuneration	-	-
Auditor's fees	<u>2,500</u>	<u>2,250</u>

3. STOCK

	2022 £	2021 £
Stock for Resale	<u>92,725</u>	<u>52,651</u>

4. PREPAYMENTS & ACCRUED INCOME

	2022 £	2021 £
Accrued income	-	3,106
Prepayments	<u>12,110</u>	<u>13,098</u>
	<u>12,110</u>	<u>16,204</u>

5. DEBTORS

	2022 £	2021 £
Trade debtors	<u>54,837</u>	<u>1,768</u>

All debtors are repayable within one year of the balance sheet date.

PROSTATE CANCER TRADING LIMITED

NOTES TO THE FINANCIAL STATEMENTS

31 MARCH 2022

6. CREDITORS: Amounts falling due within one year

	2022 £	2021 £
Amounts owed to parent undertaking	204,709	468,708
Other creditors	43,646	42,449
	<u>248,355</u>	<u>511,157</u>

7. SHARE CAPITAL

Allotted, called up and fully paid:

	2022 No	£	2021 No	£
100 Ordinary shares of £1 each	<u>100</u>	<u>100</u>	<u>100</u>	<u>100</u>

8. ULTIMATE PARENT UNDERTAKING

The company's ultimate parent undertaking is Prostate Cancer UK, a charity registered in England and Wales and in Scotland and a company limited by guarantee registered in England and Wales. The registered office is The Counting House Fourth Floor, 53 Tooley Street, London, SE1 2QN.

9. RELATED PARTY TRANSACTIONS

Exemption has been taken from the disclosure of transactions with the company's parent undertaking on the grounds that these transactions are included in consolidated accounts which are publicly available. Details of amounts owed to the parent company are given in note 6.